Literature DB >> 7055123

A two stage design for the study of the relationship between a rare exposure and a rare disease.

J E White.   

Abstract

Studies of the relationship between a rare disease and a rare exposure to a risk factor require a very large sample size to obtain reasonable estimates of risk. The cost of such studies is often prohibitive. This paper presents a less costly, two stage approach. Disease and exposure status are ascertained on a large sample in the first stage, but covariate data are collected on only a subsample in the second stage. This subsample is chosen by separately sampling from the four groups based on disease and exposure status (the diseased and exposed, the diseased and unexposed, etc.). The efficiency of this design is achieved by sampling a large proportion (or all) of the subjects from the small groups and a smaller proportion of those from the large groups. An example of a method of analyzing data from this study design, based on weighted least squares techniques, is given. Application of this new design to studies not involving a rare disease and rare exposure are discussed.

Mesh:

Year:  1982        PMID: 7055123     DOI: 10.1093/oxfordjournals.aje.a113266

Source DB:  PubMed          Journal:  Am J Epidemiol        ISSN: 0002-9262            Impact factor:   4.897


  78 in total

1.  SEMIPARAMETRIC ADDITIVE RISKS REGRESSION FOR TWO-STAGE DESIGN SURVIVAL STUDIES.

Authors:  Gang Li; Tong Tong Wu
Journal:  Stat Sin       Date:  2010-10       Impact factor: 1.261

2.  Mixed effect regression analysis for a cluster-based two-stage outcome-auxiliary-dependent sampling design with a continuous outcome.

Authors:  Wangli Xu; Haibo Zhou
Journal:  Biostatistics       Date:  2012-06-21       Impact factor: 5.899

3.  Partial linear inference for a 2-stage outcome-dependent sampling design with a continuous outcome.

Authors:  Guoyou Qin; Haibo Zhou
Journal:  Biostatistics       Date:  2010-12-14       Impact factor: 5.899

4.  Marginal structural models for case-cohort study designs to estimate the association of antiretroviral therapy initiation with incident AIDS or death.

Authors:  Stephen R Cole; Michael G Hudgens; Phyllis C Tien; Kathryn Anastos; Lawrence Kingsley; Joan S Chmiel; Lisa P Jacobson
Journal:  Am J Epidemiol       Date:  2012-02-01       Impact factor: 4.897

5.  A partial linear model in the outcome-dependent sampling setting to evaluate the effect of prenatal PCB exposure on cognitive function in children.

Authors:  Haibo Zhou; Guoyou Qin; Matthew P Longnecker
Journal:  Biometrics       Date:  2010-10-29       Impact factor: 2.571

Review 6.  Bias in occupational epidemiology studies.

Authors:  Neil Pearce; Harvey Checkoway; David Kriebel
Journal:  Occup Environ Med       Date:  2006-10-19       Impact factor: 4.402

Review 7.  Opportunities and Challenges for Environmental Exposure Assessment in Population-Based Studies.

Authors:  Chirag J Patel; Jacqueline Kerr; Duncan C Thomas; Bhramar Mukherjee; Beate Ritz; Nilanjan Chatterjee; Marta Jankowska; Juliette Madan; Margaret R Karagas; Kimberly A McAllister; Leah E Mechanic; M Daniele Fallin; Christine Ladd-Acosta; Ian A Blair; Susan L Teitelbaum; Christopher I Amos
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2017-07-14       Impact factor: 4.254

8.  Statistical Design Features of the Healthy Communities Study.

Authors:  Warren J Strauss; Christopher J Sroka; Edward A Frongillo; S Sonia Arteaga; Catherine M Loria; Eric S Leifer; Colin O Wu; Heather Patrick; Howard A Fishbein; Lisa V John
Journal:  Am J Prev Med       Date:  2015-10       Impact factor: 5.043

9.  Weighted estimating equations for longitudinal studies with death and non-monotone missing time-dependent covariates and outcomes.

Authors:  Michelle Shardell; Ram R Miller
Journal:  Stat Med       Date:  2008-03-30       Impact factor: 2.373

10.  Design and analysis of multiple events case-control studies.

Authors:  Wenguang Sun; Marshall M Joffe; Jinbo Chen; Steven M Brunelli
Journal:  Biometrics       Date:  2010-12       Impact factor: 2.571

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.